Ivonescimab
Phase 2Recruiting 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Salivary Gland Cancer
Conditions
Salivary Gland Cancer, Advanced Salivary Gland Carcinoma, Metastatic Salivary Gland Cancer, Adenoid Cystic Carcinoma
Trial Timeline
Feb 26, 2025 → Jul 1, 2027
NCT ID
NCT06805617About Ivonescimab
Ivonescimab is a phase 2 stage product being developed by Summit Therapeutics for Salivary Gland Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06805617. Target conditions include Salivary Gland Cancer, Advanced Salivary Gland Carcinoma, Metastatic Salivary Gland Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (10)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07234877 | Phase 2 | Recruiting |
| NCT07094685 | Phase 2 | Recruiting |
| NCT06959550 | Phase 2 | Recruiting |
| NCT06980077 | Phase 2 | Recruiting |
| NCT06940518 | Phase 2 | Recruiting |
| NCT06840834 | Phase 2 | Recruiting |
| NCT06925724 | Phase 2 | Recruiting |
| NCT06805617 | Phase 2 | Recruiting |
| NCT06672575 | Phase 1/2 | Recruiting |
| NCT06567314 | Phase 2 | Recruiting |
Competing Products
11 competing products in Salivary Gland Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Trastuzumab deruxtecan | Daiichi Sankyo | Phase 2 | 52 |
| enzalutamide | Astellas Pharma | Phase 2 | 52 |
| Gefitinib | AstraZeneca | Phase 2 | 52 |
| Goserelin Acetate + Pembrolizumab | Merck | Phase 2 | 52 |
| Dovitinib | Novartis | Phase 2 | 52 |
| Sacituzumab govitecan | Gilead Sciences | Phase 2 | 51 |
| Nivolumab + Ipilimumab | Bristol Myers Squibb | Phase 2 | 51 |
| Ipilimumab + Nivolumab | Bristol Myers Squibb | Phase 2 | 51 |
| Darolutamide + Goserelin | Bayer | Phase 2 | 49 |
| Cabozantinib | Ipsen | Phase 2 | 49 |
| AVA6000 | Avacta Group | Phase 1 | 25 |